Literature DB >> 17695530

Anticancer effects of licofelone (ML-3000) in prostate cancer cells.

Narayanan K Narayanan1, Dominic Nargi, Mukundan Attur, Steven B Abramson, Bhagavathi A Narayanan.   

Abstract

BACKGROUND: Licofelone, a potent antiinflammatory agent has been reported to interfere with the cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) signaling pathways with few side-effects. However, the underlying mechanism of licofelone against human cancer is not understood.
MATERIALS AND METHODS: Human and mouse prostate cancer cells were exposed to licofelone in a time- and dose-dependent manner. Cell growth/cell viability, apoptosis, and expression of COX-2 and 5-LOX at the gene and protein levels were investigated.
RESULTS: For the first time, it was demonstrated that licofelone inhibited prostate cancer cell growth and significantly down-regulated COX-2 and 5-LOX expression. A weak inhibitory effect on COX-1 protein was also observed.
CONCLUSION: Licofelone inhibited COX-2 and 5-LOX simultaneously and prevented overall cancer cell growth by enhancing apoptosis in both androgen-dependent and androgen-independent prostate cancer cells. Validating the dual role of licofelone in animal models of prostate cancer is critical for promoting its use as a potential chemopreventive or therapeutic agent.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17695530

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  11 in total

1.  Cyclooxygenase and lipoxygenase gene expression in the inflammogenesis of breast cancer.

Authors:  Brian M Kennedy; Randall E Harris
Journal:  Inflammopharmacology       Date:  2018-05-07       Impact factor: 4.473

2.  Chemoprevention of colon and small intestinal tumorigenesis in APC(Min/+) mice by licofelone, a novel dual 5-LOX/COX inhibitor: potential implications for human colon cancer prevention.

Authors:  Altaf Mohammed; Naveena B Janakiram; Qian Li; Chang-In Choi; Yuting Zhang; Vernon E Steele; Chinthalapally V Rao
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-01

3.  Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia.

Authors:  D Altavilla; L Minutoli; F Polito; N Irrera; S Arena; C Magno; M Rinaldi; B P Burnett; F Squadrito; A Bitto
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

4.  Chemopreventive efficacy and mechanism of licofelone in a mouse lung tumor model via aspiration.

Authors:  Sheela Sharma; Jin Lee; Jianliang Zhou; Vernon E Steele
Journal:  Cancer Prev Res (Phila)       Date:  2011-05-11

5.  Chemoprevention of urothelial cell carcinoma growth and invasion by the dual COX-LOX inhibitor licofelone in UPII-SV40T transgenic mice.

Authors:  Venkateshwar Madka; Altaf Mohammed; Qian Li; Yuting Zhang; Jagan M R Patlolla; Laura Biddick; Stan Lightfoot; Xue-Ru Wu; Vernon Steele; Levy Kopelovich; Chinthalapally V Rao
Journal:  Cancer Prev Res (Phila)       Date:  2014-05-02

Review 6.  Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets.

Authors:  Bei Wang; Lujin Wu; Jing Chen; Lingli Dong; Chen Chen; Zheng Wen; Jiong Hu; Ingrid Fleming; Dao Wen Wang
Journal:  Signal Transduct Target Ther       Date:  2021-02-26

Review 7.  Structure and ligand based drug design strategies in the development of novel 5- LOX inhibitors.

Authors:  Polamarasetty Aparoy; Kakularam Kumar Reddy; Pallu Reddanna
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

8.  Improved Antitumor Activity of a Therapeutic Melanoma Vaccine through the Use of the Dual COX-2/5-LO Inhibitor Licofelone.

Authors:  Silke Neumann; Simon A Shirley; Roslyn A Kemp; Sarah M Hook
Journal:  Front Immunol       Date:  2016-12-05       Impact factor: 7.561

9.  The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer.

Authors:  Masahide Matsuyama; Rikio Yoshimura
Journal:  Biologics       Date:  2008-12

10.  In Silico Approach Using Free Software to Optimize the Antiproliferative Activity and Predict the Potential Mechanism of Action of Pyrrolizine-Based Schiff Bases.

Authors:  Faisal A Almalki; Ashraf N Abdalla; Ahmed M Shawky; Mahmoud A El Hassab; Ahmed M Gouda
Journal:  Molecules       Date:  2021-06-30       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.